Biogen Inc. has announced the approval of SKYCLARYS™ (omaveloxolone) by Health Canada as the first and only treatment in Canada specifically targeting the underlying mechanisms of Friedreich ataxia $(FA)$ in patients aged 16 and older. This approval was granted under Health Canada's Priority Review process. Despite this significant milestone, Biogen has expressed disappointment over the recommendation by INESSS against listing SKYCLARYS for reimbursement in Quebec, which would leave FA patients in the province without public access to this critical treatment. The approval of SKYCLARYS marks a breakthrough for FA patients, addressing a major gap in care and offering hope for improved quality of life. The decision now awaits further consideration for reimbursement by Quebec authorities.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。